Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study - 16/09/22
Doi : 10.1016/j.jaad.2022.05.027
Urmi Khanna, MD a, Joshua Gallop, BS b, Ariana Ellis, MD a, c, Jeffery Hu, MD a, d, Abdulaziz Galadari, MD a, e, Anokhi Saklecha, BS f, Steve M. Gordon, MD g, M. Elaine Husni, MD, MPH h, Florian Rieder, MD i, Anthony P. Fernandez, MD, PhD a, j, ⁎ 
a Department of Dermatology, Cleveland Clinic, Cleveland, Ohio
b Cleveland Clinic Lerner College of Medicine, Ohio
c Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin
d Department of Dermatology, University of Wisconsin, Madison, Wisconsin
e Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
f University of California, San Diego College of Medicine, San Diego, California
g Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio
h Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio
i Department of Gastroenterology, Hepatology & Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio
j Department of Pathology, Cleveland Clinic, Cleveland, Ohio
∗Correspondence to: Anthony P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, 9500 Euclid Avenue, A61, Cleveland, OH 44195Departments of Dermatology and PathologyCleveland Clinic9500 Euclid Avenue, A61ClevelandOH44195
Key words : biologics, immune-mediated inflammatory diseases, latent tuberculosis, rescreening, seroconversion, utility
| Funding sources: Partly funded by the W.D. Steck Chair fund from the Department of Dermatology at Cleveland Clinic and supported by the W.D. Steck Chair of Clinical Dermatology fund. |
|
| Parts of this research were presented at the American College of Rheumatology annual meeting in Atlanta, GA, November 11, 2019. |
|
| IRB approval status: This project was approved by Cleveland Clinic-s IRB (#18-1329). |
|
| Reprints not available from the authors. |
© 2022
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 4
P. 841-843 - octobre 2022 Retour au numéro
Article précédent
- Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: A probability model based on a systematic review
- Atieh Jibbe, Brandon Worley, Corinne H. Miller, Murad Alam
- Skin markings to differentiate benign from malignant lesions: A prospective observational study
- Rachel Manci, Michael A. Marchetti, Stephen W. Dusza, Megan Dauscher, Ashfaq A. Marghoob
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?